Key result
IVIG infusion linked to acute STEMI in a 40-year-old female with Guillain-Barre syndrome.
Case Report (n=1)
No
IVIG infusion can rarely cause acute ST elevation myocardial infarction even in young patients without cardiac risk factors, likely due to induced hypercoagulability.
IVIG may rarely trigger STEMI even in young low-risk patients; single case report leaves open incidence and causality.
Intravenous immunoglobulin (IVIG) is used in the treatment of a variety of disorders, including autoimmune conditions. IVIG has been considered a safe medication, with minor and transient adverse effects. With the wider use of IVIG, the reported rate of adverse effects has been increased, some of them are potentially fatal cardiovascular reactions due to induction of hypercoagulable state. We report a 40-year-old female treated with IVIG for Guillain-Barre syndrome, who developed chest pain 1 hr following IVIG infusion. The symptoms were associated with ST elevation in anterior leads on electrocardiogram. This anterior wall myocardial infarction (MI) is compatible with IVIG-induced hypercoagulability and considered as a probable adverse effect of this medication. To the best of our knowledge, this is probably the first case report where a young patient developed acute MI without any cardiac risk factors after IVIG infusion.
No takes yet. Share an insight, caveat, or question.
Ruhela et al. (2014) conducted a case report in Guillain-Barre syndrome (n=1). Intravenous immunoglobulin (IVIG) was evaluated on Acute ST elevation myocardial infarction. A 40-year-old female with Guillain-Barre syndrome and no cardiac risk factors developed an acute ST elevation myocardial infarction one hour after initiating intravenous immunoglobulin infusion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: